Pfizer to lower some drug prices as White House builds "TrumpRx" website
Pfizer's CEO said President Trump's threat of tariffs motivated his company to take swift action.
Watch CBS News
Pfizer's CEO said President Trump's threat of tariffs motivated his company to take swift action.
Pfizer has agreed to offer significantly discounted prices for some prescription drugs for all American consumers and has committed to offer prescription medications to Medicaid at lower prices, President Trump announced Tuesday.
Federal health officials say thousands of updated booster shots are already being shipped around the country.
A Kaiser poll taken earlier this spring found fewer than one in five parents would get their children under 5 vaccinated right away.
The FDA's panel of vaccine advisers voted unanimously that the benefits of Pfizer's and Moderna's shots outweigh the risks in young children.
The company says it'll give U.S. regulators the data soon. Moderna is already seeking U.S. clearance to vaccinate kids 5 and under.
Citing a "robust response" of antibodies against Omicron in their vaccine trials, the companies said they were planning to submit a request "in the coming days."
Parents will have to wait a little longer for COVID-19 for their toddlers after Pfizer on Friday postponed its Food and Drug Administration application for kids under 5.
The FDA is delaying a decision on COVID-19 shots for children under 5 years of age.
Pfizer has begun a study comparing its original COVID-19 vaccine with doses specially tweaked to match the hugely contagious Omicron variant.
Antiviral pills that can significantly reduce COVID-19 hospitalizations and even deaths - but the supply of the Pfizer and Merck COVID-19 pills across the country - and here in our area - is still very limited.
"These new oral antivirals add new tools to our toolbox to keep people with COVID-19 out of the hospital," said IDPH Director Dr. Ngozi Ezike.
The CDC also recommended that kids ages 5 to 11 with moderately or severely weakened immune systems receive an additional dose 28 days after their second Pfizer shot.
The company says early results from its lab tests shows its antiviral will likely remain effective against all variants of concern, including Omicron.
The Food and Drug Administration has greenlighted a request from Pfizer and BioNTech to allow Americans as young as 16 to get a booster shot of their COVID-19 vaccine, the agency announced on Thursday, clearing a key hurdle before that age group can receive the third shot.
Pfizer is seeking authorization for its experimental COVID-19 pill after reporting it cut hospitalization and death by 90%, AP reports.
Pfizer says its COVID-19 vaccine is more than 90% effective at protecting kids from infection, ahead of public review, AP reports.
Pfizer officially submitted a request to the FDA for emergency authorization of their COVID-19 vaccine for children 5 to 11 years old.
Many people who have received Pfizer's COVID-19 vaccine are now eligible for booster shots, after the CDC gave final approval to third doses for three groups.
Pfizer says its COVID-19 vaccine works for kids ages 5 to 11. It is welcome news for many, but it also triggers a lot of questions. CBS News Chief Medical Correspondent Dr. Jon LaPook joins us with some answers on that, and on other issues surrounding the state of the pandemic.
"I'm really proud of them. Seeing them kind of courageously take this step and to do so really enthusiastically has just been a remarkable experience, not just as a pediatrician, but certainly as a dad."
Pfizer said Monday its COVID-19 vaccine works for children ages 5 to 11 and that it will seek U.S. authorization for this age group soon.
"We got our staff ready. We have the patient names ready to contact them for the booster. We are just waiting on the approval and rollout."
Full approval for the Pfizer-BioNTech COVID-19 vaccine came from the U.S. Food and Drug Administration on Monday. It came more than eight months after the FDA gave the drug authorization for emergency use.
The Food and Drug Administration announced Monday that it had granted full approval to Pfizer and BioNTech for their COVID-19 vaccine.
